Get the Stockscreener App
0.4626
0.39%
0.0018
Cytosorbents Corp stock is traded at $0.4626, with a volume of 100.99K.
It is up +0.39% in the last 24 hours and down -26.36% over the past month.
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
See More
Previous Close:
$0.4608
Open:
$0.47
24h Volume:
100.99K
Relative Volume:
1.16
Market Cap:
$29.05M
Revenue:
$37.06M
Net Income/Loss:
$-8.20M
P/E Ratio:
-3.4704
EPS:
-0.1333
Net Cash Flow:
$-12.87M
1W Performance:
-2.10%
1M Performance:
-26.36%
6M Performance:
-41.52%
1Y Performance:
-45.25%
1-Day Range:
$0.45
$0.48
1-Week Range:
$0.435
$0.48
52-Week Range:
$0.435
$1.39
Cytosorbents Corp Stock (CTSO) Company Profile
Name
Cytosorbents Corp
Sector
Industry
Phone
973-329-8885
Address
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.4626 | 28.94M | 37.06M | -8.20M | -12.87M | -0.1333 |
ABT
Abbott Laboratories
|
86.67 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
313.00 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.60 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.64 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.54 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-17-20 | Initiated | Jefferies | Buy |
| Sep-01-20 | Initiated | SVB Leerink | Outperform |
| Aug-08-17 | Reiterated | Maxim Group | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| May-24-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Upgrade | WBB Securities | Speculative Buy → Buy |
| May-12-15 | Reiterated | MLV & Co | Buy |
| Apr-01-15 | Reiterated | MLV & Co | Buy |
| Mar-05-15 | Initiated | MLV & Co | Buy |
| Feb-25-15 | Initiated | WBB Securities | Speculative Buy |
| Jan-27-15 | Reiterated | H.C. Wainwright | Buy |
View All
Cytosorbents Corp Stock (CTSO) Latest News
Why Cytosorbents (CTSO) Just Dropped -1.78% — What to Watch 2026-05-20Expert Momentum Signals - Newser
Cytosorbents Earnings Call Balances Progress and Pressure - TipRanks
Earnings call transcript: CytoSorbents Q1 2026 misses forecasts, stock falls - Investing.com
Cytosorbents (CTSO) Q1 2026 Disappoints — EPS $-0.08 Below $-0.06 ViewsDividend Growth Analysis - Newser
Cytosorbents Corporation (NASDAQ:CTSO) Q1 2026 Earnings Call Transcript - Insider Monkey
Cytosorbents Earnings Call Balances Progress And Pressure - The Globe and Mail
CytoSorbents Corp (CTSO) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth - GuruFocus
Is CytoSorbents (CTSO) a Value Trap Despite 39.9% Undervaluation - GuruFocus
CytoSorbents (CTSO) Reports Q1 Revenue Growth - GuruFocus
Transcript: CytoSorbents Q1 2026 Earnings Conference Call - Yahoo Finance
Cytosorbents Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Cytosorbents Corp 1Q 2026: Revenue $8.86M, EPS ($0.08) — 10-Q Summary - TradingView
CYTOSORBENTS ($CTSO) Releases Q1 2026 Earnings - Quiver Quantitative
CytoSorbents (CTSO) posts wider Q1 2026 loss and flags going-concern risk - Stock Titan
CytoSorbents (NASDAQ: CTSO) details DrugSorb-ATR FDA path and Q1 2026 results - Stock Titan
CytoSorbents: Q1 Earnings Snapshot - marketscreener.com
CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update - Fidelity
CytoSorbents Q1 earnings preview - MSN
CytoSorbents Corp (CTSO) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ... By GuruFocus - Investing.com Canada
Cytosorbents Corp expected to post a loss of 5 cents a shareEarnings Preview - TradingView
CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 - Quantisnow
CTSO (Cytosorbents) revenue climbs 4.1% to $37.1M in Q1 but loss widens, shares flat.Earnings Yield Analysis - Newser
CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights - BioSpace
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Aktiellt
CTSO Analyst Rating Update: HC Wainwright Lowers Price Target | - GuruFocus
Executive Compensation, Stock Options, and Corporate Governance Disclosure - Minichart
Governance, pay and ownership detailed in CytoSorbents (NASDAQ: CTSO) 10-K/A - Stock Titan
CytoSorbents implemented workforce and cost reduction program - TipRanks
Cytosorbents granted 180-day extension by Nasdaq to meet minimum bid price - Investing.com South Africa
CytoSorbents Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Nasdaq gives CytoSorbents (NASDAQ: CTSO) more time on $1 bid rule - Stock Titan
Cytosorbents (CTSO) Takes Regulatory Gamble While Insiders Remain on the Sidelines and Institutions Are Divided - Bitget
CytoSorbents Corp (HQE1.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
CytoSorbents Corp (HQE1.MU) stock price, news, quote and history - Yahoo Finance UK
CytoSorbents Corporation 2025 Annual Report: Blood Purification Technologies, Clinical Trials, and Regulatory Insights - Minichart
Cytosorbents 10-K: Revenue $37.1M, EPS not disclosed - TradingView
CytoSorbents (NASDAQ: CTSO) outlines global blood purification push and FDA path - Stock Titan
Cytosorbents’ Earnings Call Balances Progress and Risk - The Globe and Mail
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2025 Earnings Call Transcript - Insider Monkey
Cytosorbents (CTSO) Q4 2025 Earnings Transcript - AOL.com
CytoSorbents 2025 Financials: Q4 & Annual Revenue and Loss ReportNews and Statistics - IndexBox
Cytosorbents Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
H.C. Wainwright reiterates CytoSorbents stock rating at Neutral By Investing.com - Investing.com Canada
H.C. Wainwright reiterates CytoSorbents stock rating at Neutral - Investing.com
CytoSorbents Reports 2025 Financial Results: Revenue Growth, Clinical Advances, and Path to Cash Flow Breakeven in 2026 - Minichart
CytoSorbents (CTSO) Reports Slight Revenue Increase and Strategi - GuruFocus
CytoSorbents Corp (CTSO) Q4 2025 Earnings Call Highlights: Navigating Growth and Regulatory ... By GuruFocus - Investing.com Canada
CytoSorbents Corp (CTSO) Q4 2025 Earnings Call Highlights: Navigating Growth and Regulatory Challenges - GuruFocus
Earnings call transcript: CytoSorbents reports Q4 2025 earnings miss, shares dip - Investing.com Australia
Cytosorbents Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Cytosorbents (CTSO) Reports Record Sales Growth in 2025 - GuruFocus
Cytosorbents Corp Stock (CTSO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
2.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):